To further explore the role of AKT and its downstream signaling pathway in Shp2-induced drug resistance in SCLC, we examined the expression of relevant members of the AKT downstream pathway in SCLC cell lines with induced or inhibited Shp2 expression with or without cisplatin treatment. The gene discussed is AKT1; the disease is small cell lung carcinoma.